Abiopharma

🔍 LYONS GARY A (Executive)

Company: Travere Therapeutics, Inc. (TVTX)

Report Date: 2026-08-17

Detailed Transactions and Holdings:

• Acquired 5,000 shares of Common Stock at $17.44 per share (Direct)
  Date: 2026-08-17 | Code: M | equity_swap_involved: 0 | shares_owned_after: 66,500.00 | transaction_form_type: 4
• Sold 1,900 shares of Common Stock at $62.5289 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 64,600.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,600 shares of Common Stock at $63.4999 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 62,000.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 500 shares of Common Stock at $64.162 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 61,500.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Acquired 5,000 shares of Common Stock at $17.44 per share (Direct)
  Date: 2026-08-18 | Code: M | equity_swap_involved: 0 | shares_owned_after: 66,500.00 | transaction_form_type: 4
• Sold 4,100 shares of Common Stock at $63.2659 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 62,400.00 | transaction_form_type: 4 | Footnotes: F1, F5
• Sold 900 shares of Common Stock at $63.8557 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 61,500.00 | transaction_form_type: 4 | Footnotes: F1, F6
• Sold 5,000 shares of Stock option (right to buy) at $17.44 per share (Derivative)
  Date: 2026-08-17 | Code: M | Expires: 2027-05-17 | equity_swap_involved: 0 | shares_owned_after: 5,000.00 | transaction_form_type: 4 | Footnotes: F7
• Sold 5,000 shares of Stock option (right to buy) at $17.44 per share (Derivative)
  Date: 2026-08-18 | Code: M | Expires: 2027-05-17 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F7

Footnotes:

• F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.
• F2: The weighted average sale price for the transaction reported was $62.5289, and the range of prices were between $62.00 and $62.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
• F3: The weighted average sale price for the transaction reported was $63.4999, and the range of prices were between $63.01 and $63.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
• F4: The weighted average sale price for the transaction reported was $64.1620, and the range of prices were between $64.04 and $64.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
• F5: The weighted average sale price for the transaction reported was $63.2659, and the range of prices were between $62.76 and $63.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
• F6: The weighted average sale price for the transaction reported was $63.8557, and the range of prices were between $63.77 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
• F7: The stock option is fully vested and exercisable.